HERVCOV SARS-CoV-2-induced activation of pathogenic endogenous retrovirus envelope HERV-W: towards personalized treatment of COVID-19 patients
- Coordinator
- Institut National De La Sante Et De La Recherche Medicale, France
- Runs
- 1 July 2022 to 30 June 2027
- Status
- Running
- EU funding
- €6.8m
- Total cost
- €6.8m
- Partners
- 9 organisations in 5 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101057302
What the project is doing
In the project's own words, from its summary on CORDIS.
Severe COVID-19 disease and the high frequency of its long-term complications are now a major health problem worldwide. Due to the significant heterogeneity of COVID-19 disease profiles, biomarkers that allow either the identification of patients at high risk for developing severe forms of COVID-19 and its long-term complications, or guide personalized treatment options, are scarce. The HERVCOV project aims to analyze the role of human endogenous retroviruses (HERVs), known for their high pro-inflammatory potential, in the immunopathogenesis of COVID-19 and to identify and evaluate a set of biomarkers which will be important for the diagnosis, prognosis and follow-up of COVID-19 patients and their prioritization for targeted therapy.
Recent data from the consortium has demonstrated that HERV-W envelope protein is highly expressed in lymphocytes of COVID-19 patients and correlates with inflammatory markers and respiratory outcome of the disease, strongly suggesting the role of HERVs in COVID-19 pathogenesis. The project aims to assess the biological pathways and functions that underlie the association of HERV expression and activation with severe COVID-19 forms and related complications.
Biomarkers based on HERV pathogenic protein activation, SARS-CoV-2-specific immune responses, cytokine production and mandatory medical blood analyses for COVID-19 clinical monitoring will be studied in samples from different forms of COVID-19: acute, post- neuro- and long-COVID patients. Parameters will be determined that predict the clinical course of the disease and aggravation of SARS-CoV-2-induced symptoms and allow potential clustering of different bio-clinical profiles of COVID-19 patients.
Diagnostic and prognostic panel(s) ?translated? from our fundamental research and subsequent evaluations of HERV-associated biomarkers will be assessed to define novel indicators in precision medicine-based therapeutic strategies, leading to individualized medical treatment in COVID-19.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Institut National De La Sante Et De La Recherche Medicale | Paris | France | Coordinator |
| Ethniko Kai Kapodistriako Panepistimio Athinon | Athina | Greece | Participant |
| Fundacion Agencia Aragonesa Para La Investigacion Y El Desarrollo | Zaragoza | Spain | Third party |
| Instituto Aragones De Ciencias De La Salud | Zaragoza | Spain | Participant |
| Geneuro Innovation SAS | Lyon | France | Participant |
| Inserm Transfert SA | Paris | France | Participant |
| Klinicki Bolnicki Centar Rijeka | Rijeka | Croatia | Participant |
| Associazione Frascati Scienza | Frascati | Italy | Participant |
| Universita Degli Studi Di Roma Tor Vergata | Roma | Italy | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI